Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:

Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs

January 31, 2024

LUND (SWEDEN) Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, today announces the appointment of Norma Alonzo Palma, PhD as Vice President of Clinical and Medical Affairs. 


As announced in July 2023, Immunovia significantly restructured to focus its resources on the company’s next-generation blood test for early detection of pancreatic cancer. After Immunovia successfully completed the discovery phase of the new test in November 2023, Norma’s appointment will enable Immunovia to move into the next phase, where her primary responsibility will be designing and executing clinical studies as well as payer pilots.   


Norma brings over 20 years of broad experience and deep expertise in oncology, diagnostics and reimbursement. She also brings extensive experience of leading teams in planning and executing thought leader engagement, evidence-generation, and scientific communications strategies. Norma most recently held the position of VP of Medical Affairs at Aadi Biosciences where she developed and executed the medical strategy and plan. She has also held a similar position at Kaleido Biosciences, with prior leadership roles at Agios Pharmaceuticals and Foundation Medicine. 


Norma holds a Ph.D. in Pharmacology & Physiology from Georgetown University, a in Psychology and Biology from the University of California San Diego and completed her post-doctoral fellowship in molecular virology at the National Cancer Institute, Cancer Research Center, Vaccine Branch at Bethesda.  


“We are very excited to welcome Norma to Immunovia’s management team. She will play a critical role in developing and testing our next-generation product for the detection of pancreatic cancer. She will also strengthen Immunovia’s partnerships with key opinion leaders, leading clinicians, and payers”, says Jeff Borcherding, CEO and President of Immunovia. 



For more information, please contact:

Jeff Borcherding 

CEO and President  


Karin Almqvist Liwendahl

Chief Financial Officer

+46 709 11 56 08


Immunovia in brief 

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. 

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. 


USA is the world’s largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. 


Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please 



Press Release (PDF)